Ram Samudrala

US Patent:

20110112031, May 12, 2011

Filed:

Jul 11, 2008

Appl. No.:

12/668828

Inventors:

Scott F. Michael - Estero FL, US
Sharon Isern - Estero FL, US
Robert Garry - New Orleans LA, US
Ram Samudrala - Mukilteo WA, US
Joshua Costin - Naples FL, US
Ekachai Jenwitheesuk - Ratchaburi, TH

Assignee:

FLORIDA GULF COAST UNIVERSITY - Ft. Myers FL

International Classification:

A61K 38/16
C07K 14/00
C12Q 1/70
A61K 38/38
A61P 31/12

US Classification:

514 152, 530324, 514 213, 435 5

Abstract:

The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.

US Patent:

20110178003, Jul 21, 2011

Filed:

Jul 11, 2008

Appl. No.:

12/668808

Inventors:

Scott F. Michael - Estero FL, US
Sharon Isern - Estero FL, US
Joshua Costin - Naples FL, US
Ram Samudrala - Mukilteo WA, US
Ekachai Jenwitheesuk - Ratchaburi, TH

Assignee:

FLORIDA GULF COAST UNIVERSITY - Ft. Myers FL

International Classification:

A61K 38/10
C07K 7/08
C12Q 1/70
A61P 31/14

US Classification:

514 37, 530326, 514 214, 435 5

Abstract:

The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.

US Patent:

20120142623, Jun 7, 2012

Filed:

Jul 6, 2007

Appl. No.:

12/309143

Inventors:

Michael Lagunoff - Seattle WA, US
Wesley C. Van Voorhis - Seattle WA, US
Ekachai Jenwitheesuk - Ratchaburi, TH
Ram Samudrala - Mukilteo WA, US

International Classification:

A61K 31/4439
A61K 31/497
A61K 31/404
A61K 31/426
A61K 31/415
G06G 7/60
A61K 31/603
A61P 31/22
A61P 31/18
A61P 33/02
C40B 30/02
A61K 31/704
A61K 31/702

US Classification:

514 34, 514333, 51425214, 514414, 514370, 514407, 514 61, 514160, 506 8, 703 11

Abstract:

Compositions and methods are provided for predicting inhibitors of protein targets related to treatment of infectious disease, for example, bacterial, viral, or parasitic diseases. Methods are provided for predicting inhibitors of protein targets related to treatment infectious disease, for example, microbial disease, utilizing a docking with dynamics protocol to identify inhibitors, or utilizing a protein structure energy function to identify peptide or peptidomimetic inhibitors.